Comparator issue strikes again; Germany's IQWiG in doubt over GSK's Trobalt
This article was originally published in Scrip
The issue over comparators has cast a shadow over another drug undergoing Germany's early benefit assessment, GlaxoSmithKline/Valeant's Trobalt (retigabine). IQWiG, the Institute for Quality and Efficiency in Healthcare, has said that there is no proof of added benefit for the anti-epileptic after the firm chose different comparators than those wanted by the agency.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.